The Lancet Conference Alerts | Have you read our late-breaking content from BTS Winter Meeting 2025? +... ++

SERIES Prematurity-associated Lung Disease Free with registration until Dec 23, 2025 https://www.thelancet.com/series-do/prematurity-associated-lung-disease?dgcid=hubspot_email_conferencealerts_bts25_lanreslungdisease25&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-__j6UyB4FeO0Kowq3ckk2SIn7FfaUJvhYo1AflZ37P4WvA2co1LPBQvsYl9BYQZ4NGnukXAFHYM7PnRcXi4XlmMnOxsQ&_hsmi=391782178&utm_content=391782178&utm_source=hs_email ARTICLES Oral corticosteroid reduction and discontinuation in adults with corticosteroid-dependent, severe, uncontrolled asthma treated with tezepelumab (WAYFINDER): a multicentre, single-arm, phase 3b trial Open Access https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00359-5/fulltext?dgcid=hubspot_email_conferencealerts_bts25&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-8brHAOrgo0TLFYsVC8Ax2ywPyoCJVj5B8O53LPw1c46gzXm2t14B5K0tt7D4gQXKKRw4wimW0uZWFhvR5BI5vjbqKo_Q&_hsmi=391782178&utm_content=391782178&utm_source=hs_email COMMENTS Efficacy of tezepelumab in reducing oral corticosteroid use in severe asthma Free with registration until Dec 6, 2025 https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00395-9/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_bts25&_hsenc=p2ANqtz-9u6H-tPTgZsO1SDXZnNRCyiV1X2okyWdwHjjDflVzkQIqVM_JUKXT8-ef1ENcrLfX2GOK9pM0nx_Gxh0S8tyIrwKMkYQ&_hsmi=391782178&utm_content=391782178&utm_source=hs_email